City Therapeutics, Inc. Common Stock

CTY

市值 US$11.3億

關於： City Therapeutics Inc is a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics designed to silence the expression of disease-relevant proteins. Its current pipeline is focused on indications with unmet medical need, including thromboembolic diseases, Stargardt disease type 1 (Stargardt disease), and anemia of chronic disease.